Quick Answer
BioRestorative Therapies, Inc. reported R&D Expense of $10.09 million for fiscal year 2025.
BioRestorative Therapies, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.09M | +50.5% |
| 2024 | $6.71M | +66.2% |
| 2023 | $4.03M | +14.8% |
| 2022 | $3.51M | +381.9% |
| 2021 | $729.1K | -16.9% |
| 2020 | $876.8K | -49.1% |
| 2019 | $1.72M | +13.8% |
| 2018 | $1.51M | -29.7% |
| 2017 | $2.15M | -25.4% |
| 2016 | $2.88M | +37.0% |
| 2015 | $2.11M | +47.1% |
| 2014 | $1.43M | -10.3% |
| 2013 | $1.59M | +110.6% |
| 2012 | $756.8K | +6206.5% |
| 2011 | $12.0K | +3.3% |
| 2010 | $11.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.59M | +78.5% | +16.6% |
| June 30, 2025 | $2.23M | +53.1% | +29.8% |
| March 31, 2025 | $1.71M | +62.0% | +18.0% |
| September 30, 2024 | $1.45M | +79.5% | -0.0% |
| June 30, 2024 | $1.45M | +61.0% | +37.4% |
| March 31, 2024 | $1.06M | -14.1% | +30.7% |
| September 30, 2023 | $809.8K | -18.1% | -10.3% |
| June 30, 2023 | $902.9K | -16.0% | -26.7% |
- BioRestorative Therapies, Inc. showed an increase of +50.5% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, BioRestorative Therapies, Inc.’s r&d expense has grown by 86773.2% (from $11.6 thousand to $10.09 million).
- The most recent figure is from BioRestorative Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: